SP-0008: Balancing toxicity and disease control in the evolution of radiotherapy technology  by O'Sullivan, B. & Huang, S.
ESTRO 35 2016                                                                                                                                                    S3 
______________________________________________________________________________________________________ 
radiotherapy (IGRT), has highlighted deficiencies in target 
delineations based on CT. Several studies have shown large 
variability in target definitions based on CT, for multiple 
treatment sites. To address this issue, magnetic resonance 
imaging (MRI) has made its way into the clinical routine at 
modern radiotherapy departments over the last years. This, 
however, has presented several new problems that need to 
be solved. 
The traditional method of including MR information in the 
radiotherapy process is as a complement to the CT. To 
accomplish this in an integrated and accurate fashion, the 
images must be placed in a common coordinate system 
through image registration. This process in itself introduces 
new uncertainties into the treatment chain, which must be 
quantified and minimized. Another method of using MR 
information is to base the entire treatment on MR and 
exclude the CT altogether. This alleviates uncertainties that 
stem from the image registration process, but introduces 
another set of problems. To perform accurate dose 
calculations, heterogeneity corrections based on CT data 
have been the clinical standard for many years. MR data does 
not provide information that can be used for such 
corrections; however, much research effort has been 
invested in creating valid photon attenuation maps from MR 
data over the last years.  
Whatever method employed, MR for radiotherapy purposes 
also imposes practical issues that need to be addressed. The 
patient needs to be positioned in the same way that will be 
employed during the radiotherapy itself. This includes a flat 
table top and immobilization devices such as cast masks and 
tilted boards, which may not be MR compatible. For example, 
many radiotherapy fixation devices can contain metal parts 
such as nuts and bolts, which cannot be used in the MR. 
Plastic replacements must be used instead. Also, the 
standard MR coils will often not accommodate the 
immobilized patient, which forces MR adopters to acquire 
special coils or coil holders for flexible coils to be able to 
scan the patient in the radiotherapy treatment position. 
MR images do not have the same geometric integrity as CT, 
which is an issue in the radiotherapy setting. The image 
distortions can come from the machine itself or from the 
patient that is in the machine. Machine specific distortions 
are caused by inhomogeneity in the main magnetic field or 
gradient non-linearity. Patient specific distortions are mostly 
caused by susceptibility effects. The machine specific 
distortions can be measured, modelled and corrected for to a 
certain extent, while patient specific distortions often needs 
to be handled by choosing imaging parameters wisely.  
In the end, the images acquired from the MR scanner must be 
of sufficient quality to allow physicians to base the 
radiotherapy treatment on them. MR for radiotherapy has a 
different set of demands on the images than their diagnostic 
counterparts, for example slice thickness and gap, as well as 
other parameters. Also, the vast variety of MR contrasts may 
be an initial obstacle for radiotherapy oncologists. Many 
studies have shown differences in target definitions based on 
CT and MR images, and the effects of these changes in target 
volumes have not yet been studied in clinical trials. 
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Interest in proton therapy continues to grow worldwide, yet 
access to proton therapy facilities remains relatively low 
compared to those offering conventional radiotherapy. As a 
consequence, pressure exists to maximize patient throughput 
in each facility. Most facilities operate 24 hours per day, 7 
days per week to meet the demands of the clinical load and 
to complete machine maintenance, routine quality 
assurance, and patient specific quality assurance. With the 
advent of advanced delivery techniques such as pencil beam 
scanning, the complexity of patient specific quality assurance 
is increasing. However, there is a need to improve efficiency 
of these tests whilst maintaining accuracy. 
This presentation will summarize contemporary patient 
specific quality assurance practice for both passive scattering 
and pencil beam scanning proton therapy, and describe off-
line tests that potentially enable improved efficiency. 
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Radiotherapy (RT) is an effective option for treatment of 
many cancers. It offers organ and functional preservation and 
enhances surgical outcomes when administered pre-
operatively or post-operatively, and for some diseases, such 
as nasopharyngeal cancer, it is often the only curative 
option. Disease control is generally of paramount importance 
to most patients during the urgent point of decision-making 
following diagnosis. However toxicity will almost certainly 
emerge as being just as relevant in the aftermath of 
treatment and in the subsequent follow-up period. In 
essence, when a patient dies of toxicity or treatment-related 
complications, it is just as tragic as dying of disease. The 
long-term result of RTOG 9111 and 9501 suggest that 
treatment -related deaths are blunting originally observed 
difference in cancer-related outcome. The recent RTOG 0617 
trial was designed to test whether a higher RT dose (74 Gy vs 
60 Gy) +/- cetuximab could confer a survival benefit but 
showed an unexpected therapeutic “disadvantage” with 
higher RT dose attributable to significant acute and late 
toxicities. These findings highlight the importance of 
balancing toxicity and disease control to optimize 
therapeutic gain. Several strategies have been employed to 
mitigate toxicities, such as respecting the biology of 
radiation injury by altered dose fractionation (typically using 
smaller than conventional fractions), or optimising 
radiotherapy technical delivery to reduce dose to vulnerable 
anatomy. Implementing novel RT technologies need to be 
closely monitored to prove clinical benefit. Historical lessons 
have shown that putative benefits may not always transfer to 
real clinical advantages since many unforeseen factors may 
modify potential anticipated gains. While modern RT 
technologies, such as IMRT-IGRT, adaptive, and IMPT provide 
opportunities to reduce RT late toxicity by providing more 
conformal dose distribution to spatially avoid normal tissue, 
the steps to achieve this are complex. One needs to 
appreciate many diverse factors. These include radiobiology 
of normal tissue (dose/constraints), optimal imaging quality 
and registration, systematic quality control involving “target” 
delineation to delivery, and knowledge of a variety of 
inherent pitfalls in the process(e.g. poor delineation, dose 
dumping, erratic planning, tumor or normal tissue 
deformation, and set up uncertainties that may emerge 
throughout the treatment course). For example, beam path 
toxicities have been reported due to “dose dumping” from 
parotid-sparing IMRT in head and neck cancer. Increased 
local failure has been observed when delivering tight margin 
carotid-sparing partial organ irradiation for T2 glottic cancer 
using vertebrae rather than laryngeal soft tissue as the image 
guidance surrogate. Adaptive radiotherapy appears to be 
feasible in some situations but the therapeutic advantages 
are yet to be proven and may be tedious and inefficient 
under the current technical configurations of many 
departments. Also, while intensity-modulated proton therapy 
(IMPT) is an attractive emerging approach that is probably 
able to spare normal tissue, indications and clinical benefit 
are also largely unproven at this time. The path to 
implementing these approaches will require rigorous 
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attention to the radiotherapy planning and delivery 
elements, and careful systematic and prospective 
documentation of tumor and normal tissue outcomes. Even if 
randomised trials are deemed unsuited to the setting, 
protocol based approaches in registered phase I/II trials are 
appropriate to enhance standards and should probably 
include audit and quality assurance processes, as well as 
realistic stopping rules to address unexpected or aberrant 
outcomes. 
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Proton therapy is a radiation modality that has become 
increasingly available world wide over the past decade. It is 
an attractive radiotherapy intervention because of the 
charged particles dose deposition profile of characterized by 
the Bragg peak. By using proton therapy strategically, there 
is the possibility to deliver effective radiation dose to the 
target while reducing radiation to the surrounding non-target 
structures. The goals of any radiotherapy approach is to 
improve tumor control and/or reduce side effects and proton 
therapy offers an opportunity to achieve either one or both 
of these goals.Despite the promise of proton therapy, one 
must consider its associated risks and benefits, and as with 
any other radiation approach, to maximize the benefit to the 
patient. In general concepts that are useful in selecting and 
predicting a the benefit of proton therapy in individual 
patients include the following:  
1) Proton therapy has the same risk of injury within the 
target area and high dose as other radiation therapies. For 
infiltrative tumors that require irradiation of a margin of 
normal tissue (example rhabdomyosarcoma) or those that 
have normal cells embedded within the tumor (example low 
grade glioma), the tissues receiving the high dose of 
radiotherapy will have similar risks of injury as non-proton 
approaches; therefore, one would not expect a lower risk of 
injury in the high dose area.  
2) Since proton therapy is typically associated with a lower 
risk of late effectsPatient who has a very low chance of 
surviving a long time due to the natural history of the 
disease, may not benefit from proton therapy, example 
widely metastatic cancer.  
3) Patients, for example children, who can derive benefit 
from normal tissue radiation dose reduction are usually good 
candidates  
4) Patients who require high doses of radiation to achieve 
tumor control, but would otherwise be limited due to normal 
tissue tolerance, for example patients with skull base 
chordoma or primary or secondary liver.  
5) Tumor geometry and surrounding anatomy must be 
evaluated to estimate the potential benefit of proton 
therapy. For example, a 2 year old patient requiring flank 
radiation for Wilms tumor may have not benefit with proton 
therapy, whereas an 18 year old with a paravertebral Ewing's 
sarcoma may have significant advantage with proton therapy.  
6) Patient set up, tissue uncertainties, external devices or 
implanted need to be evaluated to minimize the risk of 
uncertainties and disruption in the proton dosimetry.  
7) Proton therapy may be a good option for re-irradiation in 
selected patients.In summary, proton therapy can be an 
excellent option to provide better local control and/or 
reduced toxicities in selected patients.  
 
SP-0010  
Selection of patients for proton therapy: a physicists view 
M. Hoogeman
1Erasmus Medical Center Rotterdam, Erasmus MC Cancer 
Center, Rotterdam, The Netherlands 
1, T. Arts1, S. Van de Water1, S. Van der Voort1, 
Z. Perko2, D. Lathouwers2, S. Breedveld1, B. Heijmen1 
2Delft University of Technology, Radiation Science and 
Technology, Delft, The Netherlands 
Intensity Modulated Proton therapy (IMPT) is a highly 
promising approach for radiation treatment of cancer 
patients due to its increased potential to reduce side effects 
and improve quality of life compared to contemporary 
radiation therapy techniques, such as IMRT. However, IMPT is 
associated with high costs and hence limited availability. 
Ideally, patient selection for IMPT should be based on the 
highest expected complication reduction compared to IMRT. 
For a given patient, it is possible to predict the risk of side 
effects for proton and photon therapy by applying Normal 
Tissue Complication Probabilities (NTCP) models to optimized 
dose distributions. Only patients with clinically relevant 
reductions in NTCP exceeding minimum pre-defined 
thresholds will then qualify for proton therapy. While this 
approach should guarantee effective use of proton therapy, 
there are several concerns that will be discussed in this 
presentation: 
1. The generation of a radiotherapy treatment plan is a 
complex procedure and its quality is highly dependent on the 
planner skills. To enable unbiased comparisons between IMPT 
and IMRT for each patient, automation of the treatment 
planning process is imperative. 
2. IMPT is highly susceptible to inaccuracies in patient setup, 
anatomic changes, and to uncertainties in the calculation of 
the proton range. In IMRT, uncertainties in dose delivery are 
accounted for in the CTV-to-PTV margin. In IMPT, however, 
the PTV concept is not applicable. Alternatively, robust 
treatment planning can be used to take into account patient 
setup and range uncertainties. However, it is currently 
unknown which robustness settings need to be used to 
achieve an adequate target coverage for given population-
based distributions of setup and range errors. 
3. Image-guidance technology improves the accuracy of 
radiation therapy delivery, however its impact and current 
state-of-the-art may vary for proton and photon radiotherapy 
due to the physical differences between protons and photons 
and for historical reasons. The applied image-guidance 
technology will have an impact on the magnitude of NTCP 
reduction and hence on the selection of patients qualifying 
for proton therapy. 
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The last decade, many new radiation delivery techniques 
have been clinically introduced without being subjected to 
randomized controlled trials. Many of these new techniques 
have been introduced in order to reduce the dose to the 
healthy tissues and subsequently to prevent radiation-
induced side effects. Due to its superior beam properties, 
radiotherapy with protons compared to photons enables 
similar dose administration to the target volume with 
substantially lower dose to the normal tissue. In the 
Netherlands, we applied a 4-step model-based approach to 
select patients for proton therapy and to validate the benefit 
of protons compared to photons with regard to reducing the 
risk on radiation-induced side effects.  
Step 1 consists of the development and validation of 
multivariable Normal Tissue Complication Probability (NTCP) 
models. NTCP models describe the relationship between 
radiation dose distribution parameters and the probability of 
a given side effect (NTCP-value). One of the output 
parameters of this step are the most relevant Dose Volume 
Histogram (DVH) parameters that can be used to optimize 
radiation treatment.  
Step 2 includes in silico planning comparative studies. In this 
phase protons are compared with photons with regard to 
their ability to reduce the most relevant DVH-parameters 
resulting from step 1 (∆Dose).  
Step 3: Integration step 1 and 2. By integrating the results of 
the individual in silico planning comparison into the validated 
NTCP-models, the differences in dose can be translated into 
a difference in NTCP-value in each individual patient 
